Clinical trials: Urinary System Tumor
Renal Cell Carcinoma
Healthcare Cost and Resource Utilization Related to Metastatic Renal Cell Carcinoma Treatment With Intravenous and Oral Agents
A retrospective study to evaluate healthcare cost and resource utilization for patients with metastatic renal cell carcinoma who have been treated with IV or oral agents
- Trial name
- NCT02928263
- Testing
- Non-Interventional
- Where
- United States
- Sponsor
- Bristol-Myers Squibb
Bladder Cancer, Urothelial Carcinoma
Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma
This hypothetical first-in-human study is designed to evaluate the safety, feasibility, and preliminary anti-tumor activity of an allogeneic dual-target Nectin-4/HER2 CAR-NK cell product in adults with relapsed/refractory locally…
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
- Trial name
- DUET-UC-NK (NCT07492628)
- Testing
- EB-DT-NK-UC101, Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Beijing Biotech
Metastatic Renal Cancer
Everolimus Modulation of Anti-tumor T CD4 Immune Responses
Everolimus is an inhibitor of mammalian target of rapamycin, approved in patients with metastatic renal cell carcinoma. The objective of this study is to investigated the influence of everolimus immune modulation on antitumor…
- Trial name
- EMIR (NCT02837757)
- Testing
- Biological samples
- Where
- 3 sites in France
- Volunteers
- 14 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Hepatopancreaticobiliary (HPB) Malignancy, Ovarian Cancer (OvCa)
Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
In this 2-arm, non-randomized, phase II trial, the investigators will evaluate the efficacy and safety of comprehensive multimodal prehabilitation (CMMP) alone or in combination with planned neoadjuvant (NAT) in pre-frail/frail…
- Conditions
- Hepatopancreaticobiliary (HPB) Malignancy, Ovarian Cancer (OvCa), Kidney Cancers, Bladder Cancer
- Trial name
- NCT07050771
- Testing
- Comprehensive multimodal prehabilitation (CMMP)
- Where
- United States
- Volunteers
- 148 people
- Sponsor
- The Methodist Hospital Research Institute
Neoplasms
An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma
This first time in human (FTIH) open-label, dose escalation study will assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of GSK3326595 in participants with advanced or recurrent…
- Trial name
- Meteor 1 (NCT02783300)
- Testing
- GSK3326595, Pembrolizumab
- Where
- 15 sites in United States, Canada and 2 more
- Volunteers
- 297 people
- Sponsor
- GlaxoSmithKline
Cancer
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
RATIONALE: Suberoylanilide hydroxamic acid may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.
- Trial name
- NCT00045006
- Testing
- vorinostat
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Muscle Invasive Bladder Cancer
Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
A global phase 3, multicenter, randomized, trial, to Determine the Efficacy and Safety of Durvalumab in combination with Tremelimumab and Enfortumab Vedotin or Durvalumab in combination with Enfortumab Vedotin for Perioperative…
- Trial name
- VOLGA (NCT04960709)
- Testing
- Durvalumab, Tremelimumab, Enfortumab Vedotin
- Where
- 196 sites in United States, Argentina and 23 more
- Volunteers
- 712 people
- Sponsor
- AstraZeneca
Kidney Cancer
Dolastatin 10 in Treating Patients With Advanced Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of dolastatin 10 in treating patients with advanced kidney…
- Trial name
- NCT00003914
- Testing
- dolastatin 10
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Mayo Clinic
Endoscopic Bladder Cancer Diagnosis With Raman
In Vivo Proof-of-principle Study of Raman Spectroscopy in Trial Participants With Bladder Tumours
The purpose with this clinical investigation is to perform Raman spectroscopy inside the vivid bladder and to acquire Raman spectra of normal and tumour bladder tissue, and in a post-processing step to determine the grade of the…
- Trial name
- NCT05124106
- Testing
- Raman Spectrometry
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- University Hospital Bispebjerg and Frederiksberg
Lymphoma, Metastatic Malignant Solid Neoplasm
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
This phase I trial studies the best dose and side effects of trigriluzole in combination with nivolumab and pembrolizumab in treating patients with solid malignancies or lymphoma that has spread to other places in the body or…
- Conditions
- Lymphoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Cancer
- Trial name
- NCT03229278
- Testing
- Enzyme Inhibitor Therapy, Laboratory Biomarker Analysis, Nivolumab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Rutgers, The State University of New Jersey
Urinary Bladder Tumour
Urinary Markers by SpectrosCopy: Diagnostic Aid in oncologY - Application to Urological Cancers
This study aims to evaluate the performance of vibrational spectroscopy (Infrared and Raman spectroscopy techniques) in bladder cancer diagnosis using urine samples.
- Trial name
- MUSCADE (NCT06087016)
- Testing
- Urine vibrational analysis
- Where
- France
- Volunteers
- 899 people
- Sponsor
- CHU de Reims
Bladder Cancer, Glioma
Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer
The objective of this study is to assess two novel positron emission tomography (PET) radiotracers, [64Cu]CM500 and [68Ga]CM500, for Positron Emission Tomography-Magnetic Resonance Imaging (PET-MR) and Positron Emission…
- Conditions
- Bladder Cancer, Glioma, Glioblastoma (GBM), Breast Cancer
- Trial name
- NCT07781852
- Testing
- [64Cu]CM500, [68Ga]CM500, PET/MR
- Where
- 3 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Lumina Pharmaceuticals Inc
Renal Cell Carcinoma, Immunotherapy
Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy
This Phase II trial assesses Vorolanib and Sintilimab for advanced renal cell carcinoma after previous therapy failure. Participants receive the treatment until disease progression, intolerable side effects, death, or withdrawal.
- Conditions
- Renal Cell Carcinoma, Immunotherapy, Molecular Targeted Therapy
- Trial name
- NCT06523049
- Testing
- Vorolanib Tablets, Sintilimab Injection
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Hao Zeng
Bladder Cancer
Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression
This research study is studying the safety, tolerability, and tumor activity of the study drug known as rogaratinib as a possible treatment for bladder cancer.
- Trial name
- NCT04040725
- Testing
- Rogaratinib
- Sponsor
- Dana-Farber Cancer Institute
Hematuria, Bladder Cancer
A Trial of a Modified Cystoscopy Method to Reduce Pain Perception
The goal of this project is to improve patient experience of cystoscopy using a non-pharmacologic modification of procedure. Cystoscopy is a common outpatient procedure for urology patients and is usually performed without…
- Conditions
- Hematuria, Bladder Cancer, Bladder Disease
- Trial name
- NCT03257293
- Testing
- Modified Cystoscopy, Routine Cystoscopy
- Where
- Canada
- Volunteers
- 93 people
- Sponsor
- Western University, Canada
Wilms Tumour
Collaborative Wilms Tumour Africa Project
Significant progress has been made in the treatment of Wilms tumor in high income countries, where survival is now around 85% - 90%.
- Trial name
- NCT01991652
- Where
- 3 sites in Cameroon, Ghana and 1 more
- Volunteers
- 400 people
- Sponsor
- Amsterdam UMC, location VUmc
Upper Tract Urothelial Carcinoma
Photodynamic Diagnosis of Upper Tract Urothelial Carcinoma Using Fluorescence Endoscopy and Oral 5-ALA
This study is evaluating whether a medication called 5-aminolevulinic acid (5-ALA), approved by the FDA for use in brain surgery, can help improve the visibility of upper tract urothelial tumors during surgery.
- Trial name
- NCT06948552
- Testing
- 5-Aminolevulinic acid Hydrochloride (Gliolan®)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Henry Ford Health System
Metastatic Renal Cell Carcinoma
Pazopanib in Second-line Therapy in Renal Cell Carcinoma
The principal aim of the study is to determine the objective response rate that offers the second-line treatment with pazopanib in patients with carcinoma of advanced renal cells that have progressed or that have not tolerated…
- Trial name
- NCT01577784
- Testing
- Pazopanib
- Where
- 10 sites in Spain
- Volunteers
- 27 people
- Sponsor
- Associació per a la Recerca Oncologica, Spain
Non-muscle-invasive Bladder Cancer
A Multi-National Study In Bladder Cancer Patients to Detect Recurrences After TURB (Trans-urethral Resection of the Bladder) Earlier With the Xpert Bladder Cancer Monitor Assay (ANTICIPATE X)
Bladder cancer is the 5th most common cancer in Europe, with more than 151,000 new cases diagnosed in 2012 (4% of the total). Bladder cancer has the highest recurrence rate of any malignancy, often as high as 70% within 5 years…
- Trial name
- ANTICIPATE X (NCT03664258)
- Testing
- Xpert Bladder Cancer Monitor
- Where
- 13 sites in Austria, Czechia and 7 more
- Volunteers
- 852 people
- Sponsor
- Cepheid
Bladder Cancer, Entire Ileal Conduit
Prehabilitation to Enhance Postoperative Functional Capacity Following Radical Cystectomy
The process of enhancing the functional capacity of an individual before an operation to enable him or her to withstand the stress of surgery has been termed prehabilitation.
- Conditions
- Bladder Cancer, Entire Ileal Conduit, Urinary Bladder Cancer
- Trial name
- NCT01836978
- Testing
- Prehabilitation
- Where
- Canada
- Volunteers
- 70 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre